[1]
Peyrin-Biroulet, L.; Deltenre, P.; de Suray, N.; Branche, J.; Sandborn, W.J.; Colombel, J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol., 2008, 6(6), 644-653.
[2]
Danese, S.; Fiorino, G.; Peyrin-Biroulet, L.; Lucenteforte, E.; Virgili, G.; Moja, L.; Bonovas, S. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann. Intern. Med., 2014, 160(10), 704-711.
[3]
Tracey, D.; Klareskog, L.; Sasso, E.H.; Salfeld, J.G.; Tak, P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther., 2008, 117(2), 244-279.
[5]
Blackstone, E.A.; Joseph, P.F. The economics of biosimilars. Am. Health Drug Benefits, 2013, 6(8), 469-478.
[8]
Fiorino, G.; Girolomoni, G.; Lapadula, G.; Orlando, A.; Danese, S.; Olivieri, I. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun. Rev., 2014, 13(7), 751-755.
[9]
Danese, S.; Gomollon, F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J. Crohn’s Colitis, 2013, 7(7), 586-589.
[10]
Park, W.; Hrycaj, P.; Jeka, S.; Kovalenko, V.; Lysenko, G.; Miranda, P.; Mikazane, H.; Gutierrez-Ureña, S.; Lim, M.; Lee, Y.A.; Lee, S.J.; Kim, H.; Yoo, D.H.; Braun, J. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis., 2013, 72(10), 1605-1612.
[11]
Yoo, D.H.; Hrycaj, P.; Miranda, P.; Ramiterre, E.; Piotrowski, M.; Shevchuk, S.; Kovalenko, V.; Prodanovic, N.; Abello-Banfi, M.; Gutierrez-Ureña, S.; Morales-Olazabal, L.; Tee, M.; Jimenez, R.; Zamani, O.; Lee, S.J.; Kim, H.; Park, W.; Müller-Ladner, U. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis., 2013, 72(10), 1613-1620.
[12]
Park, W.; Yoo, D.H.; Jaworski, J.; Brzezicki, J.; Gnylorybov, A.; Kadinov, V.; Sariego, I.G.; Abud-Mendoza, C.; Escalante, W.J.; Kang, S.W.; Andersone, D.; Blanco, F.; Hong, S.S.; Lee, S.H.; Braun, J. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res. Ther., 2016, 18, 25.
[13]
Yoo, D.H.; Racewicz, A.; Brzezicki, J.; Yatsyshyn, R.; Arteaga, E.T.; Baranauskaite, A.; Abud-Mendoza, C.; Navarra, S.; Kadinov, V.; Sariego, I.G.; Hong, S.S.; Lee, S.Y.; Park, W. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res. Ther., 2016, 18, 82.
[14]
Park, W.; Yoo, D.H.; Miranda, P.; Brzosko, M.; Wiland, P.; Gutierrez-Ureña, S.; Mikazane, H.; Lee, Y.A.; Smiyan, S.; Lim, M.J.; Kadinov, V.; Abud-Mendoza, C.; Kim, H.; Lee, S.J.; Bae, Y.; Kim, S.; Braun, J. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann. Rheum. Dis., 2017, 76(2), 346-354.
[15]
Yoo, D.H.; Prodanovic, N.; Jaworski, J.; Miranda, P.; Ramiterre, E.; Lanzon, A.; Baranauskaite, A.; Wiland, P.; Abud-Mendoza, C.; Oparanov, B.; Smiyan, S.; Kim, H.; Lee, S.J.; Kim, S.; Park, W. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann. Rheum. Dis., 2017, 76(2), 355-363.
[16]
Arguelles-Arias, F.; Barreiro-de-Acosta, M.; Carballo, F.; Hinojosa, J.; Tejerina, T. Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflammatory bowel disease. Rev. Esp. Enferm. Dig., 2013, 105(1), 37-43.
[17]
Annese, V.; Vecchi, M. Use of biosimilars in inflammatory bowel disease: Statements of the Italian group for inflammatory bowel disease. Dig. Liver Dis., 2014, 46(11), 963-968.
[18]
Danese, S.; Fiorino, G.; Michetti, P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J. Crohn’s Colitis, 2014, 8(11), 1548-1550.
[19]
Jorgensen, K.K.; Olsen, I.C.; Goll, G.L.; Lorentzen, M.; Bolstad, N.; Haavardsholm, E.A.; Lundin, K.E.A.; Mork, C.; Jahnsen, J.; Kvien, T.K. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet (London, England), 2017, 389(10086), 2304-2316.
[20]
Gecse, K.B.; Lovász, B.D.; Farkas, K.; Banai, J.; Bene, L.; Gasztonyi, B.; Golovics, P.A.; Kristóf, T.; Lakatos, L.; Csontos, A.A.; Juhász, M.; Nagy, F.; Palatka, K.; Papp, M.; Patai, Á.; Lakner, L.; Salamon, Á.; Szamosi, T.; Szepes, Z.; Tóth, G.T.; Vincze, Á.; Szalay, B.; Molnár, T.; Lakatos, P.L. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: A prospective, multicentre, nationwide cohort. J. Crohn’s Colitis, 2016, 10(2), 133-140.
[21]
Duron, C.; Goutte, M.; Pereira, B.; Bommelaer, G.; Buisson, A. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. Eur. J. Gastroenterol. Hepatol., 2015, 27(6), 705-711.
[22]
Farkas, K.; Rutka, M.; Bálint, A.; Nagy, F.; Bor, R.; Milassin, Á.; Szepes, Z.; Molnár, T. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis - experiences from a single center. Expert Opin. Biol. Ther., 2015, 15(9), 1257-1262.
[23]
Farkas, K.; Rutka, M.; Golovics, P.A.; Végh, Z.; Lovász, B.D.; Nyári, T.; Gecse, K.B.; Kolar, M.; Bortlik, M.; Duricova, D.; Machkova, N.; Hruba, V.; Lukas, M.; Mitrova, K.; Malickova, K.; Bálint, A.; Nagy, F.; Bor, R.; Milassin, Á.; Szepes, Z.; Palatka, K.; Lakatos, P.L.; Lukas, M.; Molnár, T. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J. Crohn’s Colitis, 2016, 10(11), 1273-1278.
[24]
Keil, R.; Wasserbauer, M.; Zádorová, Z.; Hajer, J.; Drastich, P.; Wohl, P.; Beneš, M.; Bojková, M.; Svoboda, P.; Konečný, M.; Falt, P.; Vaňásek, T.; Pešta, M.; Pešek, F.; Bouchner, L.; Koželuhová, J.; Novotný, A.; Bartůsková, L.; Špičák, J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand. J. Gastroenterol., 2016, 51(9), 1062-1068.
[25]
Park, S.H.; Kim, Y.H.; Lee, J.H.; Kwon, H.J.; Lee, S.H.; Park, D.I.; Kim, H.K.; Cheon, J.H.; Im, J.P.; Kim, Y.S.; Lee, S.Y.; Lee, S.J. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev. Gastroenterol. Hepatol., 2015, 9(Suppl. 1), 35-44.
[26]
Kang, Y.S.; Moon, H.H.; Lee, S.E.; Lim, Y.J.; Kang, H.W. Clinical experience of the use of CT-P13, a Biosimilar to infliximab in patients with inflammatory bowel disease: A case series. Dig. Dis. Sci., 2015, 60(4), 951-956.
[27]
Jung, Y.S.; Park, D.I.; Kim, Y.H.; Lee, J.H.; Seo, P.J.; Cheon, J.H.; Kang, H.W.; Kim, J.W. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J. Gastroenterol. Hepatol., 2015, 30(12), 1705-1712.
[28]
Smits, L.J.; Derikx, L.A.; de Jong, D.J.; Boshuizen, R.S.; van Esch, A.A.; Drenth, J.P.; Hoentjen, F. (R) to the Biosimilar CT-P13 in inflammatory bowel disease patients: A prospective observational cohort study. J. Crohn’s Colitis, 2016, 10(11), 1287-1293.
[29]
Jahnsen, J.; Detlie, T.E.; Vatn, S.; Ricanek, P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev. Gastroenterol. Hepatol., 2015, 9(Suppl. 1), 45-52.
[30]
Bálint, A.; Rutka, M.; Végh, Z.; Kürti, Z.; Gecse, K.B.; Banai, J.; Bene, L.; Gasztonyi, B.; Kristóf, T.; Lakatos, L.; Miheller, P.; Palatka, K.; Patai, Á.; Salamon, Á.; Szamosi, T.; Szepes, Z.; Tóth, G.T.; Vincze, Á.; Bor, R.; Milassin, Á.; Fábián, A.; Nagy, F.; Kolar, M.; Bortlik, M.; Duricova, D.; Hruba, V.; Lukas, M.; Mitrova, K.; Malickova, K.; Lukas, M.; Lakatos, P.L.; Molnár, T.; Farkas, K. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert Opin. Drug Saf., 2017, 16(8), 885-890.
[31]
Fiorino, G.; Manetti, N.; Armuzzi, A.; Orlando, A.; Variola, A.; Bonovas, S.; Bossa, F.; Maconi, G. DʼIncà, R.; Lionetti, P.; Cantoro, L.; Fries, W.; Annunziata, M.L.; Costa, F.; Terpin, M.M.; Biancone, L.; Cortelezzi, C.C.; Amato, A.; Ardizzone, S.; Danese, S.; Guidi, L.; Rizzuto, G.; Massella, A.; Andriulli, A.; Massari, A.; Lorenzon, G.; Ghione, S.; Kohn, A.; Ventra, A.; Annese, V. The PROSIT-BIO Cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm. Bowel Dis., 2017, 23(2), 233-243.
[32]
Sieczkowska, J.; Jarzębicka, D.; Banaszkiewicz, A.; Plocek, A.; Gawronska, A.; Toporowska-Kowalska, E.; Oracz, G.; Meglicka, M.; Kierkus, J. Preliminary observations. J. Crohn’s Colitis, 2016, 10(2), 127-132.
[33]
Danese, S.; Fiorino, G.; Michetti, P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization (ECCO) members: A updated survey. J. Crohn’s Colitis, 2016, 10(11), 1362-1365.
[34]
Danese, S.; Fiorino, G.; Raine, T.; Ferrante, M.; Kemp, K.; Kierkus, J.; Lakatos, P.L.; Mantzaris, G.; van der Woude, J.; Panes, J.; Peyrin-Biroulet, L. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J. Crohn’s Colitis, 2017, 11(1), 26-34.
[35]
Ben-Horin, S.; Yavzori, M.; Benhar, I.; Fudim, E.; Picard, O.; Ungar, B.; Lee, S.; Kim, S.; Eliakim, R.; Chowers, Y. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut, 2016, 65(7), 1132-1138.
77
6
1
3
